Abstract
The major mechanisms of platinum resistance at the DNA level appear to be enhanced DNA repair and increased tolerance of Pt-DNA adducts. It is clear that enhanced repair activity, as measured by removal of Pt-DNA adducts from genomic DNA, is observed in a great many platinum-resistant cell lines (1–3). This enhanced removal of Pt-DNA adducts most likely represents an increase in nucleotide excision repair capacity (4), since that is the only repair process which has been shown to remove Pt-DNA adducts. Furthermore, those cell lines with defects in nucleotide excision repair show enhanced sensitivity to platinum complexes (5,6). Recent research has defined the enzymes needed for nucleotide excision repair (7). However, it is not yet clear which of these enzymes are limiting for nucleotide excision repair in vivo and are, therefore, increased in amount and/or activity in cisplatin-resistant cell lines. For example, Dabholkar et al. (8,9) have reported increased expression of ERCC1 and XPAC in tissue from patients who were resistant to cisplatin chemotherapy. However, both Katz et al. (10) and Sheibani and Eastman (11) have found no increased expression of ERCC1 in cisplatin-resistant cell lines. Similarly, we have found no increased expression or cisplatin-inducibility of XPAC in cisplatin-resistant cell lines (Vaisman et al., manuscript in preparation).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Andrews, P.A., and Howell, S.B., Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2: 35–43, 1990.
Johnson, S.W., Ozols, R.F., and Hamilton, T.C. Mechanisms of drug resistance in ovarian cancer. Cancer, 71: 644–649,1993.
Calsou, P. and Salles, B. Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin. Cancer Chemother. Pharmacol., 32: 85–89, 1993.
Sancar, A., and Tang, M.S. Nucleotide Excision Repair. Photochem. Photobiol., 57: 905–921, 1993.
Sheibani, N., Jennerwein, M.M., and Eastman, A. DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II):host cell reactivation of damaged plasmid DNA. Biochemistry, 28: 3120–3124, 1989.
Demarcq, C., Bunch, R.T., Creswell, D., and Eastman, A. The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth Differ., 5: 983–993, 1994.
Sancar, A. Mechanisms of DNA excision repair. Science, 266: 1954–1956, 1994.
Dabholkar, M., Bostick-Bruton, F., Weber, C., Bohr, V.A., Egwuagu, C., and Reed, E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J. Nat. Cancer Inst., 84: 1512–1517, 1992.
Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J.J., and Reed, E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest., 94: 703–708, 1994.
Kratz, E.J., Andrews, P.A., and Howell, S.B. The effect of DNA polymerase inhibitors on the cytotoxicity of cisplatin in human ovarian carcinoma cells. Cancer Commun., 2: 159–164, 1990.
Sheibani, N., and Eastman, A. Analysis of various mRNAs potentially involved in cisplatin resistance of murine leukemia L1210 cells. Cancer Lett., 52: 179–185, 1990.
Zhen, W.P., Link, C.J., O’Connor, P.M., Reed, E., Parker, R., Howell, S.B., and Bohr, V.A. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol. Cell Biol, 12: 3689–3698, 1992.
May, A., Nairn, R.S., Okumoto, D.S., Wassermann, K., Stevnsner, T., Jones, J.C., and Bohr, V.A. Repair of individual DNA strands in the hamster dihydrofolate reductase gene after treatment with ultraviolet light, alkylating agents, and cisplatin. J. Biol. Chem., 268: 1650–1657, 1993.
Larminat, F., Zhen, W.P., and Bohr, V.A. Gene-specific DNA repair of interstrand cross-links induced by chemotherapeutic agents can be preferential. J. Biol. Chem., 268: 2649–2654, 1993.
Larminat, F., and Bohr, V.A. Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage. Nucleic. Acids. Res., 22: 3005–3010, 1994.
Johnson, S.W., Perez, R.P., Godwin, A.K., Yeung, AT., Handel, L.M., Ozols, R.F., and Hamilton, T.C. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem. Pharmacol., 47: 689–697, 1994.
Johnson, S.W., Swiggard, P.A., Handel, L.M., Brennan, J.M., Godwin, A.K., Ozols, R.F., and Hamilton, T.C. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and-resistant human ovarian cancer cells. Cancer Res., 54: 5911–5916, 1994.
Gibbons, G.R., Page, J.D., Mauldin, S.K., Husain, I., and Chaney, S.G. Role of carrier ligand in platinum resistance in L1210 cells. Cancer Res., 50: 6497–6501, 1990.
Schmidt, W., and Chaney, S.G. Role of Carrier Ligand in Platinum Resistance of Human Carcinoma Cell Lines. Cancer Res., 53: 799–805, 1993.
Rawlings, C.J., and Roberts, J.J. Walker rat carcinoma cells are exceptionally sensitive to cis-diamminedichloroplatinum(II) (cisplatin) and other difunctional agents but not defective in the removal of platinum-DNA adducts. Mutat. Res., 166: 157–168, 1986.
Shellard, S.A., Hosking, L.K., and Hill, B.T. Anomolous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro. Cancer Res., 51: 4557–4564, 1991.
Hill, B.T., Shellard, S.A., Hosking, L.K., Fichtinger-Schepman, A.MJ., and Bedford, P. Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diamminedichloroplatinum(II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation. Int. J. Radiat. Oncol. Biol. Phys., 19: 75–83, 1990.
Shellard, S.A., Fichtinger-Schepman, A.M.J., Lazo, J.S., and Hill, B.T. Evidence of differential cisplatin DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anti-Cancer. Drug, 4: 491–500, 1993.
Jekunen, A.P., Horn, D.K., Alcarez, J.E., Eastman, A., and Howell, S.B. Cellular pharmacology of dichloro(ethylenediamine)platinum(II) in cisplatin-sensitive and-resistant human ovarian carcinoma cells. Cancer Res., 54: 2680–2687, 1994.
Mamenta, E.L., Poma, E.E., Kaufmann, W.K., Delmastro, D.A., Grady, H.L., and Chaney, S.G. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res., 54: 3500–3505, 1994.
Eastman, A., and Schulte, N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry, 27: 4730–4734, 1988.
Wilkoff, LJ., Dulmadge, E.A., Trader, M.W., Harrison, S.D. Jr., and Griswold, D.P. Evaluation of trans-tetrachloro-1,2-diaminocyclohexane platinum (IV) in murine leukemia L1210 resistant and sensitive to cis-diamminedichloroplatinum (II). Cancer Chemother. Pharmacol., 20: 96–100, 1987.
Behrens, B.C., Hamilton, T.C., Masuda, H., Grotzinger, K.R., Whang-Peng, J., Louie, K.G., Knutsen, T., McKoy, W.M., Young, R.C., and Ozols, R.F. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res., 47: 414–418, 1987.
Teicher, B.A., Holden, S.A., Herman, T.S., Stomayor, E.A., Khandekar, V., Rosbe, K.W., Brann, T.W., Korbut, T.T., and Frei, E. III Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II). Int. J. Cancer, 47: 252–260, 1991.
Perez, R.P., O’Dwyer, P.J., Handel, L.M., Ozols, R.F., and Hamilton, T.C. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines. Int. J. Cancer, 48: 265–269, 1991.
Hills, C.A., Kelland, L.R., Abel, G., Riracky, J., Wilson, A.P., and Harrap, K.R. Biological properties of ten human ovarian cell lines: calibration in vitro against four platinum complexes. Br. J. Cancer, 59: 527–534, 1989.
Page, J.D., Husain, I., Sancar, A., and Chaney, S.G. Effect of the diammocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry, 29: 1016–1024, 1990.
Kohn, K.W., and Grimek-Ewig, R.A. Alkaline elution analysis, a new approach to the study of DNA single-strand interuptions in cells. Cancer Res., 33: 1849–1853, 1973.
Micetich, K., Zwelling, L.A., and Kohn, K.W. Quenching of DNA:platinum(II) monoadducts as a possible mechanism of resistance to cis-diamminedichloroplatinum(II) in L1210 cells. Cancer Res., 43: 3609–3613, 1983.
Fram, R.J., Woda, B.A., Wilson, J.M., and Robichaud, N. Characterization of acquired resistance to cis-diamminedichloroplatinum(II) in BE human colon carcinoma cells. Cancer Res., 50: 72–77, 1990.
Hospers, G.A.P., Mulder, N.H., de Jong, B., de Ley, L., Uges, D.R.A., Fichtinger-Schepman, A.M.J., Scheper, R.J., and de Vries, E.G.E. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res., 48: 6803–6807, 1988.
Richon, V.M., Schulte, N., and Eastman, A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res., 47: 2056–2061, 1987.
Strandberg, M.C., Bresnick, E., and Eastman, A. The significance of DNA cross linking to cis-diamminedichloroplatinum(II)-induced cytotoxicity in sensitive and resistant lines of murine leukemia L1210 cells. Chem.-Biol. Interact., 39: 169–180, 1982.
Strandberg, M.C., Bresnick, E., and Eastman, A. DNA crosslinking induced by 1, 2-diaminocyclohexanedichloroplatinum(II) in murine leukemia L1210 cells and comparison with other platinum analogs. Biochim. Biophys. Acta, 698: 128–133, 1982.
Kaufmann, W.K. Pathways of human cell post-replication repair. Carcinogenesis, 10: 1–11, 1989.
Hoffmann, J.-S., Johnson, N.P., and Villani, G. Conversion of monofunctional DNA adducts of cis-diamminedichloroplatinum(II) to bifunctional lesions. J. Biol. Chem., 264: 15130–15135, 1989.
Comess, K.M., Burstyn, J.N., Essigmann, J.M., and Lippard, S.J. Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts. Biochemistry, 31: 3975–3990, 1992.
Gibbons, G.R., Kaufmann, W.K., and Chaney, S.G. Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells. Carcinogenesis, 12: 2253–2257, 1991.
Jennerwein, M.M., Eastman, A., and Khokhar, A.R. Characterization of adducts produced in DNA by isomeric l, 2-diaminocyclohexaneplatinum(II) complexes. Chem.-Biol. Interact., 70: 39–49, 1989.
Fichtinger-chepman, A.M.J., Vendrik, C.P.J., van Dijk-Knijnenburg, W.C.M., De Jong, W.H., van der Minnen, A.C.E., Claessen, A.M.E., van der Velde-Visser, S.D., de Groot, G., Wubs, K.L., Steerenberg, P.A., Schornagel, J.H., and Berends, F. Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats innoculated with cisplatin-sensitive or resistant immunoglobulin M immunocytoma. Cancer Res., 49: 2862–2867, 1989.
Salles, B., Butour, J.L., Lesca, C., and Macquet, J.P. cis-Pt(NH3)2Cl2 and trans-Pt(NH3)2Cl2 inhibit DNA synthesis in cultured L1210 leukemia cells. Biochem. Biophys, Res. Commun., 112: 555–563, 1983.
Sorenson, C.M. and Eastman, A. Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cel 1 cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res., 48: 6703–6707, 1988.
Just, G., and Holler, E. Platinum incorporation and differential effects of cis-and trans-diamminedichloroplatinum(II) on the growth of mouse leukemia P388/D1. Cancer Res., 49: 7072–7077, 1989.
Boyer, J.C., Kaufmann, W.K., Brylawski, B.P., and Cordeiro-Stone, M. Defective post-replication repair in Xeroderma pigmentosum variant fibroblasts. Cancer Res., 50: 2593–2598, 1990.
Zinkewich-eotti, K., and Andrews, P.A. Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine-123 resistance. Cancer Res., 52: 1902–1906, 1992.
Wassermann, K., Kohn, K.W., and Bohr, V.A. Heterogeneity of nitrogen-mustard-induced DNA damage and repair at the level of the gene in Chinese hamster ovary cells. J. Biol. Chem., 265: 13906–13913, 1990.
Matsuo, N., and Ross, P.M. Measurement of interstrand cross-link frequency and distance between interruptions in DNA exposed to 4,5′,8-trimethylpsoralen and near-ultraviolet light. Biochemistry, 26: 2001–2009, 1987.
Kohn, K.W. Molecular mechanisms of cross-linking by alkylating agents and platinum complexes. In: A.C. Sartorelli, J.S. Lazlo and J.R. Bertino (eds.), Molecular actions and targets for cancer chemotherapeutic agents, pp. 3–16, New York: Academic Press. 1981.
Holler, E., Bauer, R., and Bernges, F. Monofunctional DNA-platinum(II) adducts block frequently DNA polymerases. Nucleic. Acids Res., 20: 2307–2312, 1992.
Naegeli, H. Roadblocks and detours during DNA replication: Mechanisms of mutagenesis in mammalian cells. Bioessays, 16: 557–564, 1994.
Sweasy, J.B., Witkin, E.M., Sinha, N., and Roegner-Maniscalco, V. RecA protein of Escherichia coli has a third essential role in SOS mutator activity. J. Bacteriol., 172: 3030–3036, 1990.
Frank, E.G., Hauser, J., Levine, A.S., and Woodgate, R. Targeting of the UmuD, UmuD’, and MucA’ mutagenesis proteins to DNA by RecA protein. Proc. Natl. Acad. Sci. USA, 90: 8169–8173, 1993.
Hurwitz, J., Dean, F.B., Kwong, A.D., and Lee, S.-H. The in vitro replication of DNA containing the SV40 origen. J. Biol. Chem., 265: 18043–18046, 1990.
O’Day, C.L., Burgers, P.M.J., and Taylor, J.S. PCNA-induced DNA synthesis past cis-syn and trans-syn-I thymine dimers by calf thymus DNA polymerase delta in vitro. Nucleic. Acids Res., 20: 5403–5406, 1992.
Hughes, E.N., Engelsberg, B.N., and Billings, P.C. Purification of nuclear proteins that bind to cisplatin-damaged DNA — Identity with high mobility group protein-1 and protein-2. J. Biol Chem., 267: 13520–13527, 1992.
Donahue, B.A., Augot, M., Bellon, S.F., Treiber, D.K., Tonry, J.H., Lippard, S.J., and Essigmann, J.M. Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. Biochemistry, 29: 5872–5880, 1990.
Brown, S.J., Kellett, P J., and Lippard, S.J. Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science, 261: 603–605, 1993.
Andrews, P.A. and Jones, J.A. Characterization of binding proteins from ovarian carcinoma and kidney tubule cells that are specific for cisplatin modified DNA. Cancer Commun., 3: 93–102, 1991.
Vaisman, A., and Chaney, S.G. Induction of UV-damage recognition protein by cisplatin treatment. Biochemistry, 34: 105–114, 1995.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Chaney, S.G., Mamenta, E.L. (1996). DNA Repair and the Carrier Ligand Specificity of Platinum Resistance. In: Pinedo, H.M., Schornagel, J.H. (eds) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0218-4_31
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0218-4_31
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0220-7
Online ISBN: 978-1-4899-0218-4
eBook Packages: Springer Book Archive